Update shared on 05 Nov 2025
Narrative Update: Philogen Price Target Revision
Analysts have maintained Philogen's fair value estimate at €26.00. Adjustments in future revenue growth and profit margin expectations are key supporting factors for this unchanged target.
What's in the News
- Philogen completed repurchase of 29,448 shares between May 7, 2025 and September 22, 2025. This represents 0.07% of the company and was completed for €0.66 million under the buyback announced on May 12, 2025 (company filing).
Valuation Changes
- Fair Value remains unchanged at €26.00.
- Discount Rate holds steady at 8.83%.
- Revenue Growth is projected to decline sharply from -8.58% to -22.49%.
- Net Profit Margin is expected to increase substantially, rising from 8.28% to 44.69%.
- Future P/E is estimated to decrease considerably from 250.25x to 76.07x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.